X4 Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript
Good morning, everyone, and thank you for joining us on day four of the virtual Cantor Healthcare Conference. My name is Emma Nealon, and I am one of the small/mid-cap biotech analysts here Cantor. It is my pleasure to be hosting X4 Therapeutics this morning for a fireside chat. And joining us today from X4 is CEO, Paula Ragan.
So let's start with a brief overview of X4 and your lead asset, mavorixafor. Where did the asset come from? And maybe walk us through the mechanism of action.
Sure. Good morning, Emma, and thanks so much for hosting us at the Cantor conference. We appreciate it. So you know we are really excited about our lead asset, mavorixafor. It is a drug that impacts and modulates the immune system, which you can appreciate has tremendous potential as we think about it here, and certainly in the last year and a half that we've all lived through. In terms of what CXCR4 -- the target -- it does in the healthy state is it helps regulate the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |